At a glance
- Originator Daiichi Pharmaceutical
- Class Antibacterials; Quinolones
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 28 Dec 2000 Discontinued-Preclinical for Bacterial infections in Japan (Unknown route)
- 09 Oct 1998 New profile
- 09 Oct 1998 Preclinical development for Bacterial infections in Japan (Unknown route)